Literature DB >> 1573267

Macrophage inflammatory protein 1 modulates macrophage function.

T J Fahey1, K J Tracey, P Tekamp-Olson, L S Cousens, W G Jones, G T Shires, A Cerami, B Sherry.   

Abstract

Macrophage inflammatory protein 1 (MIP 1), initially purified from the conditioned medium of endotoxin-stimulated macrophages, is a low m.w. heparin-binding protein doublet comprising two peptides, MIP 1 alpha and MIP 1 beta. Although native doublet MIP 1 has previously been shown to exert pyrogenic, mitogenic, and proinflammatory effects on other cell types, its actions on its cell of origin, the macrophage, have not been well catalogued. Our study reports several aspects of macrophage function that are modulated by MIP 1. MIP 1 was not directly cytotoxic for WEHI tumor cells, but MIP 1-treated macrophage exhibited enhanced antibody-independent macrophage cytotoxicity for tumor targets. MIP 1 treatment stimulated proliferation of mature tissue macrophages, and this effect was enhanced upon costimulations with either CSF-1 or granulocyte-macrophage-CSF. Thioglycollate-elicited peritoneal exudate macrophages incubated with native doublet MIP 1-secreted bioactive TNF and IL-6, as well as immunoreactive IL-1 alpha, and these effects were enhanced significantly when the cells were costimulated with IFN-gamma. Purified preparations of the recombinantly derived MIP 1 alpha peptide alone stimulated the secretion of TNF, IL-1 alpha, and IL-6 by peritoneal macrophages, but MIP 1 beta did not. In fact, as little as eightfold excess MIP 1 beta blocked TNF-induction by MIP 1 alpha to a significant degree. By contrast to these apparent "macrophage activating" properties of MIP 1, the cytokine failed to trigger the macrophage oxidative burst, or to up-regulate the expression of Ia on the macrophage surface. Taken together, these data reveal that MIP 1 peptides act as autocrine modulators of their cells of origin, and raise the possibility that MIP 1 peptides may play a role in modulating macrophage responses to inflammatory stimuli in vivo.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1573267

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  100 in total

1.  Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection.

Authors:  W Gao; P S Topham; J A King; S T Smiley; V Csizmadia; B Lu; C J Gerard; W W Hancock
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

2.  Suppression subtractive hybridization identifies distinctive expression markers for coronary and internal mammary arteries.

Authors:  Minghui Qin; Zhaohui Zeng; Jie Zheng; Prediman K Shah; Stephen M Schwartz; Lawrence D Adams; Behrooz G Sharifi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-01-30       Impact factor: 8.311

3.  Modulation of cytokine and chemokine secretions in rhesus monkey trophoblast co-culture with decidual but not peripheral blood monocyte-derived macrophages.

Authors:  Ann E Rozner; Svetlana V Dambaeva; Jessica G Drenzek; Maureen Durning; Thaddeus G Golos
Journal:  Am J Reprod Immunol       Date:  2011-01-31       Impact factor: 3.886

4.  Toward a novel experimental model of infection to study American cutaneous leishmaniasis caused by Leishmania braziliensis.

Authors:  Tatiana R de Moura; Fernanda O Novais; Fabiano Oliveira; Jorge Clarêncio; Almério Noronha; Aldina Barral; Claudia Brodskyn; Camila I de Oliveira
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

5.  An unusual pro-inflammatory role of interleukin-10 induced by arabinosylated lipoarabinomannan in murine peritoneal macrophages.

Authors:  Nivedita Majumder; Ranadhir Dey; Ram Kumar Mathur; Sriparna Datta; Madhumita Maitra; Sanjukta Ghosh; Bhaskar Saha; Subrata Majumdar
Journal:  Glycoconj J       Date:  2006-12       Impact factor: 2.916

6.  Monocyte chemotactic protein-1 promotes inflammatory vascular repair of murine carotid aneurysms via a macrophage inflammatory protein-1α and macrophage inflammatory protein-2-dependent pathway.

Authors:  Brian L Hoh; Koji Hosaka; Daniel P Downes; Kamil W Nowicki; Cristina E Fernandez; Christopher D Batich; Edward W Scott
Journal:  Circulation       Date:  2011-10-17       Impact factor: 29.690

7.  CCL3 augments tumor rejection and enhances CD8+ T cell infiltration through NK and CD103+ dendritic cell recruitment via IFNγ.

Authors:  Frederick Allen; Iuliana D Bobanga; Peter Rauhe; Deborah Barkauskas; Nathan Teich; Caryn Tong; Jay Myers; Alex Y Huang
Journal:  Oncoimmunology       Date:  2017-11-20       Impact factor: 8.110

8.  Phase I evaluation of the safety, pharmacokinetics and pharmacodynamics of CP-481,715.

Authors:  Alan T Clucas; Ajit Shah; Yuanchao Derek Zhang; Vincent F Chow; Ronald P Gladue
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 9.  Chemokines in joint disease: the key to inflammation?

Authors:  J J Haringman; J Ludikhuize; P P Tak
Journal:  Ann Rheum Dis       Date:  2004-04-13       Impact factor: 19.103

10.  The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial.

Authors:  Peter W Hunt; Nancy S Shulman; Timothy L Hayes; Viktor Dahl; Ma Somsouk; Nicholas T Funderburg; Bridget McLaughlin; Alan L Landay; Oluwatoyin Adeyemi; Lee E Gilman; Brian Clagett; Benigno Rodriguez; Jeffrey N Martin; Timothy W Schacker; Barbara L Shacklett; Sarah Palmer; Michael M Lederman; Steven G Deeks
Journal:  Blood       Date:  2013-04-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.